Background
Testicular cancer is the most common cancer among teenagers and young men between the ages of 15 and 35. Approximately 80% of patients can be cured with current therapies. However these therapies have not changed greatly since the mid-1980s and are very toxic. This results in substantial long-term side effects that greatly impact quality of life for many decades. In addition, 15-20% of patients cannot be cured even with the cytotoxic drugs and die.
